Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...
The Washington State Employment Security Department said in the filing that 72 employees will be laid off on Jan. 17. A ...
Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Hosted on MSN8h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Gilead Sciences, seeing a 22% boost, benefited from regulatory wins in treatments for liver disease and HIV. The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback